Results from a retrospective analysis of the phase III SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer who had a poor prognosis.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe